Travatrelvir - Traws Pharma
Alternative Names: 83-0060; MPro; Ratutrelvir; Ratutrelvir - Traws Pharma; TRX 01Latest Information Update: 07 Oct 2024
At a glance
- Originator Trawsfynydd Therapeutics
- Developer Traws Pharma
- Class Antivirals; Small molecules
- Mechanism of Action Coronavirus 3C-like proteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 30 Sep 2024 Pharmacokinetics and adverse events data from a phase I trial in COVID-2019 infections released by Traws Pharma
- 15 Aug 2024 Trawsfynydd Therapeutics plans a phase II trial in COVID-2019 infections, in H2 2024 or first quarter of 2025
- 23 May 2024 Efficacy data from a phase I trial in COVID-2019 infections released by Traws Pharma